VYNE Therapeutics (NASDAQ:VYNE) Releases Earnings Results, Misses Expectations By $0.03 EPS

VYNE Therapeutics (NASDAQ:VYNE) posted its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03), Zacks reports. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%.

VYNE Therapeutics Stock Performance

Shares of VYNE stock traded up $0.07 on Thursday, hitting $2.38. 38,744 shares of the company’s stock traded hands, compared to its average volume of 81,002. The company’s fifty day simple moving average is $2.80 and its 200 day simple moving average is $2.50. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.30. The stock has a market capitalization of $35.03 million, a price-to-earnings ratio of -2.76 and a beta of 1.13.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VYNE. BTIG Research started coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a research report on Wednesday, February 19th.

Insider Transactions at VYNE Therapeutics

In other VYNE Therapeutics news, Director Patrick G. Lepore purchased 15,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average cost of $2.92 per share, with a total value of $43,800.00. Following the acquisition, the director now owns 51,472 shares in the company, valued at approximately $150,298.24. This trade represents a 41.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.80% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.